Proton Pump Inhibitors Market, by Type (Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, and Others), by Disease Indication (Ulcers, Gastroesophageal Reflux Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Ph

Proton Pump Inhibitors Market, by Type (Omeprazole, Pantaprazole, Rabeprazole, Dexlansoprazole, lansoprazole, and Others), by Disease Indication (Ulcers, Gastroesophageal Reflux Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

The global proton pump inhibitor market includes various drugs which are prescribed by healthcare professionals for treatments related to various gastrointestinal disorders such as duodenal ulcers, peptic ulcers, NSAIDS induced ulcers, and gasteroesophageal reflux disease. Proton pump inhibitors are a class of drugs that act on cell lining of stomach and reduce stomach acid in patients suffering from gastro-intestinal disorders. Proton pump inhibitors include drugs such as esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazol.
Market Dynamics
The global proton pump inhibitor market is expected to witness significant growth during the forecast period owing to focus of generic drug manufactures on obtaining approvals and launching products for treatment of gastro-intestinal diseases to strengthen their position in the global proton inhibitor market. For instance, in March 2020, Rosemont Pharmaceuticals, a pharmaceutical company, launched omeprazole powder for oral suspension, PPI approved for use on mg/kg basis and used in treatment of patients in age groups such as pediatric, adults. The omeprazole powder oral suspension is also licensed for use with percutaneous endoscopic gastonomy (PEG) and nasograstic (NG) tubes.
Key features of the study:
This report provides in-depth analysis of the global proton pump inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global proton pump inhibitor market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A., Aurobindo Pharma, Perrigo Company plc, Dr. Reddy's Laboratories
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, market expansion, and marketing tactics
The global proton pump inhibitor market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global proton pump inhibitor market.
Detailed Segmentation:
Global Proton Pump Inhibitor Market, By Type:
Omeprazole
Pantaprazole
Rabeprazole
Dexlansoprazole
lansoprazole
Others
Global Proton Pump Inhibitor Market, By Disease Indication:
Ulcers
Gastroesophageal Reflux Disease
Others
Global Proton Pump Inhibitor Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Global Proton Pump Inhibitor Market, By Region:
North America
By Type:
Omeprazole
Pantaprazole
Rabeprazole
Dexlansoprazole
lansoprazole
Others
By Disease Indication:
Ulcers
Gastroesophageal Reflux Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
By Country:
U.S.
Canada
Latin America
By Type:
Omeprazole
Pantaprazole
Rabeprazole
Dexlansoprazole
lansoprazole
Others
By Disease Indication:
Ulcers
Gastroesophageal Reflux Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type:
Omeprazole
Pantaprazole
Rabeprazole
Dexlansoprazole
lansoprazole
Others
By Disease Indication:
Ulcers
Gastroesophageal Reflux Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type:
Omeprazole
Pantaprazole
Rabeprazole
Dexlansoprazole
lansoprazole
Others
By Disease Indication:
Ulcers
Gastroesophageal Reflux Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type:
Omeprazole
Pantaprazole
Rabeprazole
Dexlansoprazole
lansoprazole
Others
By Disease Indication:
Ulcers
Gastroesophageal Reflux Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
By Country/Region:
GCC
Israel
Rest of Middle East
Africa
By Type:
Omeprazole
Pantaprazole
Rabeprazole
Dexlansoprazole
lansoprazole
Others
By Disease Indication:
Ulcers
Gastroesophageal Reflux Disease
Others
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
AstraZeneca PLC/AB *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Novo Nordisk A/S
Bayer AG
Pfizer Inc.
Cadila Pharmaceuticals Limited
Eisai Pharmaceuticals India Pvt. Ltd
Santarus, Inc.
Wyeth, LLC
Janssen Pharmaceutica
Takeda Pharmaceutical Company Limited
Sanofi S.A.
Aurobindo Pharma
Perrigo Company plc
Dr. Reddy's Laboratories
Aralez Pharmaceuticals Inc.
RedHill Biopharma Ltd (ADR)
Cipla Limited
“*” marked represents similar segmentation in other categories in the respective section.